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[10_TD$DIFF]Abstract
The search for novel anticancer therapeutics with the ability to overcome
multi-drug resistance (MDR) mechanisms is of high priority. A class of
molecules that show potential in overcoming MDR are the N-alkylated isatins.
In particular 5,7-dibromo-[11_TD$DIFF]N-alkylisatins are potent microtubule destabilizing
agents that act to depolymerize microtubules, induce apoptosis and inhibit
primary tumor growth in vivo. In this study we evaluated the ability of four [12_TD$DIFF]
dibrominated N-alkylisatin derivatives and the parent compound,
5,7-dibromoisatin, to circumvent MDR. All of the isatin-based compounds
examined retained potency against the MDR cell lines; U937VbR and
MES-SA/Dx5 and displayed bioequivalent dose-dependent cytotoxicity to that
of the parental control cell lines. We show that one mechanism by which the
isatin-based compounds overcome MDR is by circumventing P-glycoprotein
(P-gp) mediated drug efflux. Thus, as the isatin-based compounds are not
susceptible to extrusion from P-gp overexpressing tumor cells, they represent
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a promising alternative strategy as a stand-alone or combination therapy for
treating MDR cancer.
Keywords: Medicinal chemistry, Cancer treatment, Cell biology
1. Introduction
Advances in molecular targeted anticancer agents over the past two decades
have significantly improved outcomes for cancer patients. However, a major
clinical obstacle to successful treatment has been the emergence of pleiotropic
or multi-drug resistance (MDR), a phenomenon responsible for the decrease in
efficacy of clinically used chemotherapeutics [1, 2]. MDR occurs when cancer
cells become resistant to a variety of structurally and functionally unrelated
anticancer agents even if the patient has not previously been exposed to that
drug. An important molecular driver for MDR is overexpression of the plasma
membrane glycoprotein (P-gp) [3]. P-gp is the gene product of ABCB1, a
member of the ABC (ATP binding cassette) superfamily of transporter proteins,
that acts as an ATP-dependent efflux pump preventing adequate intracellular
accumulation of a large number of cytotoxic drugs including vinca alkaloids [4],
taxanes [5, 6], anthracyclines [7], epipodophyllotoxins, camptothecins [8] and
some of the newer molecular targeted anticancer drugs such as imatinib [9, 10],
sorafenib [11] and everolimus [12]. Innate or acquired overexpression of P-gp is
now a marker of chemoresistance and disease progression in a growing number
of solid and hematologic malignancies [13, 14, 15].
The classic pharmacological strategy to overcome P-gp mediated efflux has been
the co-administration of efflux pump inhibitors and cytotoxic agents in an effort
to increase the intracellular concentration of cytotoxic drugs to lethal doses.
Although several P-gp inhibitors have been evaluated in clinical trials they have
all failed to date, attributable to lack of specificity, resulting in off-target organ
accumulation and intolerable side effects [16]. For example, verapamil,
a calcium channel blocker that also competitively inhibits P-gp transport of
other substrates, is associated with cardiotoxicity at doses required to reverse
MDR [17]. Cyclosporin A (CSA) causes increased nausea, vomiting,
hypomagnesemia and myelosuppression [18] and second generation P-gp
modulators such as valspodar, a cyclosporin D derivative that inhibits P-gp with
10- to 20-fold greater activity than CSA, significantly increases toxicity in
patients with recurring and refractory multiple myeloma [19]. Given this, the
search for novel therapeutics that are not substrates for drug efflux mechanisms
and therefore not susceptible to extrusion from P-gp overexpressing tumor cells
is of high priority and a promising alternative strategy [20].
A group of cytotoxins that show potential in overcoming MDR are those
based on the isatin (1H-indole-2,3-dione) scaffold. For example,
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isatin-β-thiosemicarbazones have recently been identified to selectively kill
P-gp overexpressing tumor cells in vitro [21, 22]. The lead compound
(NSC73306) was effective in the National Cancer Institute 60 cell line (NCI-60)
drug screen with de novo or acquired P-gp induced MDR and acted indirectly
to resensitize cells to previously ineffective agents [23, 24]. Other isatin
derivatives that display promising anticancer activities include those derived
from 5,7-dibromoisatin (1; Fig. 1). The synthesis and subsequent cytotoxic
evaluation of a library of N-alkylisatins (mainly N-arylalkylisatins) led to the
discovery that a number of these compounds possess sub-micromolar cytotoxic
activity (IC50) against a panel of human cancer cell lines [25, 26, 27]. One
compound, 5,7-dibromo-N-(p-trifluoromethylbenzyl)[3_TD$DIFF]isatin, was even shown to
preferentially kill lymphoma and leukemic cancer cell lines over freshly
isolated, non-transformed human peripheral blood lymphocytes [26]. Mode of
action studies revealed that N-alkyl-5,7-dibromoisatins arrest cells in the G2/M
phase and induce apoptosis via activation of the caspase 3/7 cascade [25, 26].
Furthermore, tubulin binding experiments demonstrated that N-alkyl-5,7-
dibromoisatins destabilize microtubule growth as evidenced by the inhibition of
microtubule polymerization in the presence of structurally diverse N-alkylisatins.
Considering the role microtubule targeting chemotherapeutics play in the
treatment and control of cancer, the development of novel microtubule agents
that retain potency against MDR tumors is likely to have significant clinical
impact in the future.
In this study we sought to evaluate the cytotoxicity of a number of
5,7-dibromo- [11_TD$DIFF]N-alkylisatins (2-5; Fig. 1) with varied substituents at the isatin
nitrogen, against the human lymphoma (U937) and uterine sarcoma (MES-SA)
[(Fig._1)TD$FIG]
Fig. 1. Chemical structures of 5,7-dibromoisatin (1) and the N-alkylisatin derivatives 5,7-dibromo-
N-(p-hydroxymethylbenzyl) [3_TD$DIFF]isatin (2); 5,7-dibromo-N-(p-phenylbenzyl)[3_TD$DIFF]isatin (3); 5,7-dibromo-N-
(p-cinnamyl) [3_TD$DIFF]isatin (4) and 5,7-dibromo-N-(napthalen-1-ylmethyl) [3_TD$DIFF]isatin (5) and the commercial
anticancer agents paclitaxel, doxorubicin, vinblastine and colchicine.
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cell lines and their corresponding MDR sublines (U937VbR and MES-SA/Dx5,
respectively). The ability of these compounds to modulate P-gp ATPase
activity was also studied to further elucidate direct drug - P-gp interactions in
an effort to assess their potential as new drug candidates for treating MDR
cancer.
2. Materials and methods
2.1. Reagents and chemicals
5,7-Dibromoisatin (1) and the N-alkylated derivatives 5,7-dibromo-N-(p-
hydroxymethylbenzyl) [3_TD$DIFF]isatin (2); 5,7-dibromo-N-(p-phenylbenzyl) [3_TD$DIFF]isatin (3);
5,7-dibromo-N-(p-cinnamyl)[3_TD$DIFF]isatin (4) and 5,7-dibromo-N-(-naphthalen-1-
ylmethyl)[3_TD$DIFF]isatin (5) were synthesized as described previously [25, 26].
Vinblastine sulfate, colchicine, paclitaxel, doxorubicin, rhodamine-123,
calcein-AM, cyclosporine A, verapamil, anti-P-gp monoclonal antibody F4 and
FITC-conjugated goat anti-mouse IgG were purchased from Sigma-Aldrich
(Australia). The Pgp-GloTM assay and CellTiter 96 AQueous One Solution Cell
Proliferation Assay (MTS) were purchased from Promega Corporation
(Australia).
2.2. Cell lines and culture conditions
The human histiocytic lymphoma (U937), uterine sarcoma parental (MES-SA)
and multi-drug resistant subline (MES-SA/Dx5) were purchased from the
American Type Culture Collection (ATCC, USA), distributed by Cryosite,
Australia. The MES-SA/Dx5 cell line was selected by continuous in vitro
exposure to doxorubicin [28] and was chosen for use in this study as its
P-gp-mediated resistance by over-expression of ABCB1 is well documented
[28, 29]. U937 cells were routinely cultured in RPMI-1640 medium (Invitrogen,
USA) containing 5–10% (v/v) fetal calf serum (FCS, Thermo, USA) and the
MES-SA cell lines were cultured in DMEM/F12 medium (Invitrogen, USA)
containing 10% FCS and supplemented with 2 mM L-glutamine. Cells were
maintained in culture at 37 °C, 95% humidity, 5% CO2, in a Heracell incubator
(Kendro Laboratory Products, Germany). The drug resistant U937 subline,
U937VbR, was generated in-house through continuous low dose exposure
(beginning with 60 nM and increasing to 120 nM) of vinblastine sulfate in
culture media. The U937VbR cells underwent >20 passages in the presence of
vinblastine in order to develop and maintain a resistant phenotype. Cells were
harvested by centrifugation at 300 × g for 5 min and viable cells, based on
trypan blue exclusion, counted using a hemocytometer. All cell lines were
confirmed negative for mycoplasma contamination.
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2.3. PCR and cell-based analyses of resistance mechanisms
2.3.1. Real-time quantitative PCR (RT-qPCR)
Analysis of ABCB1 mRNA levels was performed by RT-qPCR. Total RNA was
extracted from cells using the ISOLATE RNA mini kit (Bioline, Australia) as
per manufacturer's instructions. Aliquots of RNA (1 μg) were reverse transcribed
using SensiFASTTM cDNA Synthesis Kit (Bioline, Australia) as per
manufacturer's instructions. The 5x TransAmpTM Buffer provided in the kit
included a blend of anchored oligo dT and random hexamer primers to ensure
unbiased 3′ and 5′ coverage for enhanced data accuracy. The cDNA synthesis
reaction was carried out in the total volume of 20 μL in the Eppendorf
Mastercycler Pro (Eppendorf, Australia) with the following program: 25 °C for
10 min (primer annealing), 42 °C for 15 min (reverse transcription), 85 °C for
5 min (inactivation), 4 °C hold (or chill on ice). The RT-qPCR was performed
on all cell lines using SYBR® Green PCR master mix (Applied Biosystems,
Australia) and run on the Lightcycler480 (Roche, Australia). Primers used
for the amplification of the target ABCB1 gene (forward 5′-
AGTGAAAAGGTTGTCCAAG-3′ and reverse 5′-AGTCTGCATTCTGGATGG-
3′) and the internal reference gene, β-actin (forward 5′-
GAATTCTGGCCACGGCTGCTTC-3′ and reverse 5′-
AAGCTTTTTCGTGGATGCCACA-3′), were the predesigned KiCqStart®
SYBR® Green Primers purchased from Sigma, Australia. The RT-qPCR
reaction was conducted in the total volume of 20 μL in a 96 well Plate
(LightCycler® 480 Multiwell Plate 96 white, Roche Diagnostics, Australia)
with the primer concentration of 440 nM. Cycle conditions were as follows:
pre-incubation 1 cycle (95 °C for 5 min), amplification 45 cycles (95 °C for
10 sec, 55 °C for 10 sec and 72 °C for 20 sec), melting curve 1 cycle (95 °C
for 5 sec and 65 °C for 1 min), cooling 1 cycle (40 °C for 10 sec). The amount
of ABCB1 mRNA expression was normalised to β-actin and the relative
quantification of ABCB1 was calculated according to the comparative
quantification cycle (Cq) method as described by Applied Biosystems using
RNA isolated from MES-SA/Dx5 cell line as the internal calibrator. PCR
products were subjected to electrophoresis on a 2% agarose gel and were
visualized by ethidium bromide staining to confirm size (data not shown).
2.3.2. Cell surface P-gp expression
Cell surface expression of P-gp was analyzed by flow cytometry. Briefly,
1 × 105 cells/100 μL in PBS (1% w/v BSA) were incubated with either
anti-P-gp monoclonal antibody F4 (diluted 1:1000) or a matched mouse isotype
control in the absence (MES cell lines) or presence (U937 cell lines) of FcR
block (20% v/v) for 30 min on ice, followed by three washes with ice cold PBS
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with 1% BSA and 0.1% NaN3. Cells were then incubated with FITC-conjugated
goat anti-mouse IgG (diluted 1:200) for 30 min on ice in the dark, again
followed by three washes with PBS. Cells were resuspended in PBS and the
fluorescence intensity of FITC-conjugated antibody analyzed by flow cytometry
(LSR II flow cytometer; BD Biosciences, San Diego, CA) (excitation 488 nm,
emission collected with 515/20 band-pass filter), using FlowJo software
(version 10; Tree Star Inc., Ashland, OR) to evaluate cell surface expression of
P-gp. Analysis was made comparing anti-P-gp monoclonal antibody F4 to the
isotype control to account for nonspecific binding and presented as a fold
increase compared to parental cell lines.
2.4. Cell viability assays
In vitro cell viability assays were performed in 96-well microtiter plates as
described by Vine et al. [26] using the CellTiter 96 Aqueous One Solution
Cell Proliferation Assay, employing [3-(4,5-dimethylthiazol-2-yl)-5-(3-
carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium, inner salt] (MTS).
Compounds 1-5 and commercial anticancer drugs were serially diluted in
DMSO (final concentration 2.5%) or PBS and incubated with sensitive or drug
resistant cell lines for 48 h. IC50 values (the dose required to inhibit the
metabolic activity of 50% of the cell population) were calculated from
logarithmic sigmoidal dose response curves generated using GraphPad Prism
v6 software (GraphPad Inc.). Data is presented as a mean ± standard deviation
(SD) from ≥2 independent experiments, performed in triplicate. The resistance
index (RI) was calculated to determine the degree of acquired resistance of each
cell line to its selective drug and the cross resistance developed to other drugs.
RI was calculated based on the following equation:
RI ¼ IC50 resistant sublineð Þ
IC50 parental cell lineð Þ
2.5. P-gp mediated efflux assays
2.5.1. Rhodamine 123
The presence of an active efflux pump, P-gp, was probed on U937VbR cells
using the fluorescent P-gp substrate, rhodamine 123 (R123), in the absence or
presence of cyclosporine A (CSA) or verapamil, specific P-gp inhibitors. Cells
(5000–10,000/well) were seeded in 96-well microplates at a volume of 100 μL
and incubated at 37 °C for 24 h prior to addition of R123 (5 μM) in the absence
or presence of CSA (20 μM), verapamil (20 μM), PBS or DMSO vehicle
control (final concentration 2.5% v/v). Cells were incubated at 37 °C for a
further 40 min in the dark. Culture media was removed and the cells washed
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with ice-cold PBS (pH 7.4). Cells were lysed with 1% Triton-X, and an aliquot
(80 μL) added to wells of a 96-well black plate. Fluorescence was then
measured using an excitation wavelength of 485 nm, and emission wavelength
of 530 nm using a FLUOstar Optima (BMG Labtech, Germany). Fluorescence
measurements were normalised to protein content in each well as determined by
a Lowry protein determination assay (BioRad, Australia).
2.5.2. Calcein-AM
Non-fluorescent calcein-AM is converted to a green-fluorescent calcein by
intracellular esterases. The degree of inhibition of P-gp activity can be
quantified by measuring the increase in intracellular calcein fluorescence.
MES-SA/Dx5 cells (25,000/well) were seeded in 96-well microplates at a
volume of 100 μL and incubated at 37 °C, 5% CO2 for 24 h prior to addition
of CSA (40 μM), compounds 1-5 (40 μM) or DMSO vehicle control (final
concentration 2% v/v), with calcein-AM (1 μM) added immediately after. Cells
were further incubated for 40 min at 37 °C before being imaged on the
IncuCyte ZOOM (Essen BioScience USA) using the phase and green filters at
20 × magnification (1392 × 1040, 0.61 μm/pixel, acquisition time 400 ms). All
treatments were in triplicate and 4 images per well were acquired (total n = 12).
The approximate number of cells scanned was 300-400 cells per image.
IncuCyte ZOOM 2015A software was used to determine the fraction of calcein
positive cells (defined as cells with a green pixel intensity greater than that
observed for cells not incubated with calcein (i.e. green pixel intensity
>10 GCU)) by dividing the average green fluorescence confluence by the
average cell confluence.
[13_TD$DIFF]2.6. Cell morphology
The ability of the N-alkylisatins to maintain their mode of action and disrupt
microtubule dynamics was determined in the MDR resistant U937VbR subline
using light microscopy. Vinblastine (60 nM), colchicine (10 nM) or representative
N-alkylisatins 2, 4 and 5 (2.5 μM) were incubated with U937 or U937VbR cells
for 24 h and changes in cell morphology compared to control treated cells.
2.7. P-gp ATPase assay
The effect of compounds 1-5 on P-gp ATPase activity was measured using the
Pgp-GloTM assay system. Verapamil, a P-gp substrate and competitive inhibitor
for other substrates, was used as a positive control. Sodium orthovanadate
(Na3VO4), a selective inhibitor of P-gp ATPase, was used to account for
P-gp-independent ATP consumption in the reactions. All compounds and
controls were tested at either 40 μM or 200 μM (in 1% DMSO) as per the
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manufacturer's protocol. Sample luminescence was recorded after 50 min
incubation with the ATP detection reagent using a luminometer (POLARstar
Omega, BMG Labtech, Ortenberg, Germany). Change in luminescence in
relative light units (RLU; RLUNa3VO4–RLUcompound) is inversely proportional to
ATP levels, which are negatively correlated with the activity of P-gp ATPase
and therefore P-gp-mediated transport.
2.8. Statistical analysis
Data is presented as a mean ± SD based on two or more independent
experiments, performed in triplicate. One-way analysis of variance (ANOVA)
using a Dunnett's multiple comparisons post-test or t-tests were used to
determine the significance among groups (GraphPad Prism 6.01). P-values
< 0.05 were considered significant.
3. Results
3.1. U937VbR and MES-SA/Dx5 overexpress ABCB1 mRNA
and its protein product P-gp
In order to ascertain if P-gp mediated efflux contributes to the mechanism of
resistance of our newly generated U937VbR cell line to the commercial
anticancer drugs vinblastine, colchicine, paclitaxel and doxorubicin, as well as
compounds 1-5, we probed for expression of the ABCB1 gene, coding for P-gp,
by RT-qPCR. The U937VbR cells exhibited a 765-fold increase in ABCB1
mRNA transcript levels compared to the parental U937 cells (Fig. 2A), which
were similar to that expressed in the control MES-SA/Dx5 multi-drug resistant
cell line, previously reported to highly express P-gp [29]. Increased ABCB1
mRNA expression was associated with a 3-4-fold increase in cell surface
expression of P-gp on both resistant cell lines compared to their parental
controls (Fig. 2B) as determined by immunofluorescence staining and flow
cytometry. This result was also confirmed by assessing the uptake and retention
of the fluorescent P-gp substrate R123 (Supplementary Information, Fig. S1).
The fluorescent compound was incubated with cells in the presence or absence
of two P-gp inhibitors. Extrusion of R123 substantially decreased in the
presence of CSA or [14_TD$DIFF]verapamil in the U937VbR subline.
3.2. [15_TD$DIFF]N-Alkylisatins retain potency against MDR cancer cell
lines
3.2.1. Cell viability
The degree of cross resistance to a single concentration of the commercial
anticancer agents vinblastine, colchicine, paclitaxel and doxorubicin was
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determined in the U937VbR and MES-SA/Dx5 MDR sublines using the MTS
cell proliferation assay, prior to screening the isatin compounds 1-5. Both the
U937VbR and MES-SA/Dx5 cell lines exhibited a significant decrease in
sensitivity compared to parental control cell lines (U937 and MES-SA) to all
four cytotoxic chemotherapeutics at 100 nM, with a 3-5-fold decrease in
potency for the microtubule targeting drugs (vinblastine, colchicine and
paclitaxel) and 1.1-5.0-fold decrease in potency for the topoisomerase inhibitor
(doxorubicin) (Fig. 3A & B). The U937VbR subline exhibited the greatest
resistance to vinblastine and colchicine with a 4.2 ± 0.3 and 4.9 ± 0.5-fold
decrease in drug sensitivity, respectively. Conversely the MES-SA/Dx5 subline
displayed the greatest resistance to doxorubicin and paclitaxel with a 5.0 ± 0.6
and 4.7 ± 0.3-fold decrease in drug sensitivity, respectively after 48 h.
Comparison of the dose response curves for the isatin derivatives (1-5) against
the MDR cell lines U937VbR and MES-SA/Dx5 found them to be bioequivalent
to their respective chemosensitive cell lines at both 24 h (Fig. S2;
Supplementary Information) and 48 h (Fig. 4 and Fig. 5). This was irrespective
[(Fig._2)TD$FIG]
Fig. 2. U937VbR and MES-SA/Dx5 overexpress ABCB1 mRNA and its protein product P-gp.
(A) Real-time quantitative PCR (RT-qPCR) of the ABCB1 mRNA transcript level in MES-SA,
MES-SA/Dx5, U937 and U937VbR cell lines. Raw expression values were normalized to the
internal reference gene, β-actin and expressed as a fold increase to respective cells lines. (B) Fold-
increase in P-gp. Immunofluorescent staining of P-gp on the surface of parental and resistant cell
lines as determined by flow cytometry. Values are the mean (± SD) of triplicates.
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of the compounds' molecular weight, lipophilicity, N-alkylation and substitution
pattern. This was in stark contrast to the commercial anticancer [16_TD$DIFF]agents
vinblastine (Fig. 4F) and doxorubicin (Fig. 5F). No significant difference in the
IC50 values of compounds 1-5 were observed between resistant and parental
cells lines, while vinblastine, paclitaxel and doxorubicin all exhibited a
significant decrease in potency against the P-gp overexpressing U937VbR and
MES-SA/Dx5 MDR cell lines (Table 1).
3.2.2. Cell morphology
We have previously reported that lymphocytic cell lines display characteristic
changes and elongated cell morphology after treatment with N-alkylisatins
targeting tubulin polymerization [25, 26, 30]. We therefore monitored the
morphology of resistant and parental U937 cell lines after treatment with the
commercial microtubule targeting drugs, vinblastine and colchicine and
[(Fig._3)TD$FIG]
Fig. 3. U937VbR and MES-SA/Dx5 cell lines exhibit cross resistance to the anticancer drugs
vinblastine, colchicine, paclitaxel and doxorubicin. Cell viability of (A) U937 (black bars) or
U937VbR (grey bars) and (B) MES-SA (black bars) or MES-SA/Dx5 (grey bars) after 48 h
treatment with 0.1 μM of the commercial anticancer agents vinblastine, colchicine, paclitaxel and
doxorubicin. Values are the mean (± SEM) of triplicates.
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compared this to three representative N-alkylisatins which are known to alter
cell shape. Chemoresistant U937VbR cells treated with 60 nM vinblastine or
10 nM colchicine exhibited morphologies identical to vehicle control treated
U937 and U937VbR cells (Fig. 6) indicating abrogation of activity. Conversely,
the morphology of U937VbR cells treated with the N-alkylisatin [5_TD$DIFF]based
microtubule destabilizers 2, 4 and 5 was consistent with that observed for the
chemosensitive parental U937 cell line (Fig. 6G–L) and demonstrates
maintenance of activity and mode of action against this MDR cell line.
[(Fig._4)TD$FIG]
Fig. 4. Dose-dependent cytotoxicity of the isatin [4_TD$DIFF]derivatives 1-5 is maintained in the vinblastine
resistant U937 (U937VbR) subline. Cells were incubated with increasing concentrations of either
(A) 5,7-dibromoisatin (1), (B) 5,7-dibromo-N-(p-hydroxymethylbenzyl)[3_TD$DIFF]isatin (2), (C) 5,7-dibromo-
N-(p-phenylbenzyl)[3_TD$DIFF]isatin (3), (D) 5,7-dibromo-N-(p-cinnamyl) [3_TD$DIFF]isatin (4), (E) 5,7-dibromo-N-
(naphthalen-1-ylmethyl)[3_TD$DIFF]isatin (5) or (F) vinblastine (as a control). The relative sensitivity of the
U937 (black) and U937VbR (red) cell lines to the drugs was determined by MTS assay after 48 h
incubation. Values are the mean (± SEM) of triplicates.
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3.3. [15_TD$DIFF]N-Alkylisatins are not substrates or inhibitors of P-gp
3.3.1. Calcein-AM efflux assay
The intracellular accumulation of the fluorescent reporter calcein was used to
assess the functional activity of P-gp in the MDR MES-SA/Dx5 cell line in the
presence of compounds 1-5. Non-fluorescent, hydrophobic calcein-AM enters
the lipid bilayer and is pumped out of the cell by P-gp, reducing the
intracellular concentration of calcein-AM. Modulators of P-gp activity reduce
[(Fig._5)TD$FIG]
Fig. 5. Dose-dependent cytotoxicity of the isatin [4_TD$DIFF]derivatives 1-5 is maintained in doxorubicin
resistant MES-SA (MES-SA/Dx5) subline. Cells were incubated with increasing concentrations of
either (A) 5,7-dibromoisatin (1), (B) 5,7-dibromo-N-(p-hydroxymethylbenzyl)[3_TD$DIFF]isatin (2), (C) 5,7-
dibromo-N-(p-phenylbenzyl)[3_TD$DIFF]isatin (3), (D) 5,7-dibromo-N-(p-cinnamyl) [3_TD$DIFF]isatin (4), (E) 5,7-dibromo-
N-(napthalen-1-ylmethyl) [3_TD$DIFF]isatin (5) or (F) colchicine (as a control). The relative sensitivity of the
MES-SA (black) and MES-SA/Dx5 (red) cell lines to the drugs was determined by MTS assay after
48 h incubation. Values are the mean (± SEM) of triplicates.
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Table 1. N-alkylisatins retain potency against the MES-SA/Dx5 and U937VbR MDR cancer cell lines.
IC50 (μM) ± SD RI
Compound U937 U937VbR MES-SA MES-SA/Dx5 U937VbR:U937 MES-SA/Dx5:MES-SA
1 16.00
(± 5.57)
24.64
(± 2.13)
17.25
(± 2.51)
15.01
(± 0.22)
1.5 0.9
2 1.52
(±1.44)
2.84
(±2.38)
0.49
(± 0.55)
0.39
(±0.31)
1.9 0.8
3 2.02
(±1.64)
2.22
(±1.73)
2.74
(± 2.42)
1.89
(±1.48)
1.1 0.7
4 1.48
(± 0.05)
2.24
(± 0.83)
1.08
(± 0.77)
0.90
(± 0.64)
1.5 0.8
5 1.81
(± 1.49)
2.83
(± 2.11)
0.241
(± 0.02)
0.311
(± 0.01)
1.6 1.3
Vinblastine 0.0032
(± 0.00)
0.241
(± 0.02)
0.0034
(± 0.02)
0.082
(± 0.02)
75 24
Doxorubicin – – 0.727
(± 0.20)
6.70
(± 2.57)
– 9.2
Paclitaxel 0.001
(± 0.001)
0.122
(±0.033)
– – 122 –
- [7_TD$DIFF] Not tested.
[(Fig._6)TD$FIG]
Fig. 6. N-alkylisatins retain their mode of action against the vinblastine resistant U937VbR
subline. Morphological effects of commercial and N-alkylisatin [5_TD$DIFF]based microtubule destabilizers on
U937 and U937VbR cells. Cells were treated with either (A/B) DMSO vehicle control, (C/D) 60 nM
vinblastine, (E/F) 10 nM colchicine or 2.5 μM of the N-alkylisatins (G/H) 5,7-dibromo-N-(p-
hydroxymethylbenzyl) [3_TD$DIFF]isatin (2), (I/J) 5,7-dibromo-N-(p-cinnamyl) [3_TD$DIFF]isatin (4) and (K/L) 5,7-dibromo-
N-(naphthalen-1-ylmethyl)[3_TD$DIFF]isatin (5) for 24 h. Images were obtained by brightfield microscopy on an
inverted light microscope at 40x magnification.
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the rate of calcein AM efflux, leading to increased intracellular calcein AM,
which is then hydrolyzed by intracellular esterases, converting it to the
fluorescent product calcein. Free calcein is hydrophilic and thus retained inside
the cells. After 40 min the proportion of calcein positive cells was 1.5 times
greater for cells treated with the P-gp inhibitor CSA than for cells treated with
the vehicle control (P = 0.0014; Fig 7A). No significant increase in intracellular
accumulation of calcein was seen after incubation with compounds 1-5
compared to the vehicle control, indicating that isatins do not inhibit P-gp.
3.3.2. P-gp ATPase assay
In order to further confirm that compounds 1-5 do not directly interact with
P-gp, we measured the change in luminescence associated with P-gp ATPase
hydrolysis. Compounds that do not directly interact with P-gp have no effect on
basal ATPase activity; compounds that are substrates for transport by P-gp
stimulate basal ATPase activity while inhibitors decrease basal ATPase
activity. Verapamil is a substrate for P-gp transport and showed a significant
increase in the change in luminescence (RLUNa3VO4–RLUverapamil) at 40 μM and
200 μM (P < [17_TD$DIFF]0.05 and P < 0.01, respectively) compared to basal activity
(RLUNa3VO4–RLUuntreated), which represents verapamil-stimulated P-gp ATPase
activity (Fig. 7). Compounds 1-5 did not show a significant change in
luminescence compared to basal activity; therefore, N-alkylisatins do not
interact with P-gp.
4. Discussion
MDR has become a major barrier to the clinical efficacy of a wide range of
chemotherapeutic drugs, prompting the development of new strategies in cancer
treatment [31, 32, 33, 34]. The N-alkylisatins are part of a continually growing,
diverse family of potent cytotoxins which show activity in vitro against cancers
that are often associated with clinical resistance. Further, investigations in vivo
have identified 5,7-dibromo-N-(p-trifluoromethylbenzyl)[3_TD$DIFF]isatin to be efficacious
in an orthotopic human breast carcinoma xenograft mouse model [30] and
highlights the importance of further investigations into this class of compounds
in the context of MDR. In determining the ability of the N-alkylisatins to
overcome MDR, a vinblastine resistant U937 cell line, previously shown to be
sensitive to N-alkylisatins, was established as a model of clinically-developed,
acquired chemoresistance due to continuous drug exposure. Vinblastine was
chosen as it is a microtubule destabilizer and exhibits a similar mode of action
to that of the N-alkylisatins [26]. It was also chosen for the potential to
successfully create an MDR phenotype with broad cross-resistance, as cell lines
resistant to the Vinca alkaloids have been shown to exhibit decreased sensitivity
to a number of structurally unrelated small-molecule anticancer agents, such as
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colchicine and anthracyclines [35, 36, 37]. The mechanism of resistance is
primarily due to over-expression of the efflux pump protein, P-gp [1, 38].
We found the most effective method for inducing vinblastine resistance in
the U937 cell line was through continuous low dose exposure to 120 nM
vinblastine, excluding a recovery period in drug-free media. A resistance index
(RI) of 75 was observed for vinblastine and cross-resistance to structurally
unrelated chemotherapeutics such as colchicine, paclitaxel and doxorubicin was
[(Fig._7)TD$FIG]
Fig. 7. N-Alkylisatins are not substrates or inhibitors of P-gp. (A) Relative effect of the isatins
on Pgp-mediated extrusion of Calcein AM. Cells (MES-SA/Dx5) were incubated with compounds
1-5 (40 μM), CSA (40 μM) or vehicle control (2% v/v) for 40 min. Data is normalized to CSA
treated cells (100% inhibition) and presented as the mean ± SD (n = 12) determined using live cell
imaging (IncuCyte ZOOM). ***[6_TD$DIFF]P < 0.001; ns = not significant. (B) Effect of test compounds on
P-gp ATPase activity. P-gp membranes in the presence of compounds 1-5 (in 1% DMSO) or
verapamil (positive control) at either 40 μM or 200 μM were treated with MgATP as per the
Pgp-GloTM assay protocol. Change in luminescence in relative light units (RLU) was calculated by
subtracting the RLU of each test compound from the RLU of sodium orthovanadate (selective
inhibitor of P-gp ATPase) to correct for P-gp independent ATP consumption. Change in
luminescence is inversely proportional to ATP levels, which are negatively correlated with the
activity of P-gp ATPase and therefore P-gp-mediated transport. Red line indicates basal activity.
Data are presented as the mean ± SD (n = 3). **P < 0.01; *P < 0.05; ns = not significant.
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clearly demonstrated (Fig. 3; Table 1). Marked upregulation of the ABCB1 gene
and decreased uptake and retention of the P-gp substrate R123 was observed in
the U937VbR cell line suggesting that P-gp mediated drug efflux plays a role in
the chemoresistance profile observed in this new subline. Other mechanisms of
resistance to microtubule-binding agents such as the Vinca alkaloids and taxanes
include alterations to their microtubule targets. Mechanisms such as mutations
in the binding motifs in α- or β-tubulin, or upregulation of alternative tubulin
isotypes such as βIII tubulin have been shown to be important in driving
paclitaxel and vincristine resistance in non-small-cell lung cancer however
reasons for this are still poorly understood [39]. Cross-resistance of such
mechanisms, however, appear to be limited to tubulin-binding agents only,
suggesting that they are not the determinant of the MDR phenotype observed in
response to continuous exposure to vinblastine in this study. This is supported
by our cell morphology studies (Fig. 6) which indicates that there has been no
change in the intracellular microtubule target of the isatins under the selection
pressure of the microtubule disrupting agent vinblastine. Further, the breast
cancer resistance protein (BCRP) [40], another ATP-binding cassette transporter
capable of inducing drug resistance, does not confer resistance to the Vinca
alkaloids, epipodophyllotoxins, paclitaxel, or cisplatin [41] suggesting that it is
unlikely to be contributing to the MDR phenotype observed in our MDR
subline. While our data is consistent with overexpression of ABCB1 as the
major efflux mechanism responsible for the resistant phenotype observed in the
U937VbR cell line in this study, the expression of other efflux pumps such as
multidrug resistance associated-protein 1 (MRP1) should also be profiled to
fully complete characterization.
Four structurally diverse N-alkylisatin analogues (2-5) and the parent
dibromoisatin molecule (1) were chosen for use in this study due to the
N-alkylisatins' relatively high potency and synthetic availability. Furthermore,
while P-gp and MRP are capable of extruding a wide variety of anticancer
compounds, they can't remove them all, with structures containing the indole
core featuring heavily in a growing number of anticancer and antibacterial
compounds that are not substrates of, or can reverse drug efflux mechanisms
[21, 42, 43]. The cytotoxic effect of compounds 1-5 was therefore evaluated in
our in vitro MDR model system to determine their potential susceptibility to
P-gp-mediated efflux. Two different parental cell lines were used; one derived
from human histiocytic lymphoma and the other from human uterine sarcoma,
as MDR screening is most often performed in model systems which employ
cell lines derived from hematological malignancies while the use of cell lines
derived from solid tumors is usually less popular [29]. The IC50 values obtained
for all 5 isatin-based compounds against the U937VbR and MES-SA/Dx5 MDR
sublines were not statistically different to those observed for the parental control
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cell lines. Further, the dose response profiles were virtually superimposable and
not statistically different by 2 way ANOVA, which was in contrast to the dose
response profiles of the commercial anticancer agents, suggesting that this
class of molecule is not susceptible to P-gp-mediated efflux over concentrations
ranging from 100 nM- 100 μM. Importantly, the growth properties of the
resistant cell lines were identical to that of the parental cell lines
(Supplementary Information Fig. S3) suggesting that differences in cell
population doubling time (rate of mitosis) did not impact on our findings.
Our results corroborate those reported by Hall et al. who describe isatin-
β-thiosemicarbazones to be neither substrates nor inhibitors of P-gp, but which
also act to reduce P-gp expression [21, 22]. While the effect of isatins 1-5 on
the expression of P-gp was not interrogated in this study, experiments are
underway to investigate the effect on ABCB1 expression in U937 and MES-SA
cell lines after long-term, continuous culture with 5,7-dibromo-N-(p-
hydroxymethylbenzyl) isatin (2). Preliminary findings suggest continuous
exposure to increasing concentrations of compound 2 over a period of 4 months
does not result in significant upregulation of ABCB1 and cells maintain drug
sensitivity (Supplementary Information Fig. S4).
Research within our laboratory has demonstrated that N-benzylation of
5,7-dibromoisatin substantially increases cytotoxic activity in vitro by up to two
orders of magnitude against a range of human cancer cell lines [25, 26]. Using
pharmacophores, Hall et al. identified the aromatic/hydrophobic groups at the
N4 position of the thiosemicarbazone, as well as the isatin moiety, to be
important features for the maintenance of MDR-selective activity [21, 22]. In
this study, structure activity relationship experiments found that alkylation at the
N1 position increased cytotoxic activity as reported [25, 26], but had no effect
on MDR-selective activity, confirming reliance on the isatin core. While the
mechanisms by which the isatins overcome MDR have not yet been elucidated,
we can hypothesize that may they include poor P-gp substrate affinity, ability to
alter the biophysical properties of the plasma membrane or enter the cell via
alternative drug uptake mechanisms.
5. Conclusions
The emergence of resistance to clinical cancer treatments poses a significant
problem in the management and treatment of cancer. While combination
therapies are showing promise, there is still a need to develop more
efficacious therapeutics that are able to overcome resistance mechanisms
employed by tumor cells. The potential novel interaction of the N-alkylisatins
with tubulin, together with their high potency in vitro and ability to inhibit
tumor growth in vivo, point to the importance of further investigations into
these compounds.
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